Skip to main content
Figure 2 | BMC Nephrology

Figure 2

From: Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

Figure 2

Pharmacodynamic variables. Data correspond to patients who received 100 IU/Kg of Heberitro (solid line) or Eprex (dashed line). (A): average reticulocyte counts increments; (B): percentage mean reduction in serum iron. Standard deviations are not shown for the sake of simplicity of the illustration.

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us